# Abcuro, Inc.

> Abcuro is a clinical-stage biotechnology company in Newton, Massachusetts developing first-in-class immunotherapies that selectively deplete highly cytotoxic T cells implicated in autoimmune tissue damage and certain cancers. Its lead program, ulviprubart (ABC008), is a monoclonal antibody targeting the KLRG1 receptor, advanced primarily for inclusion body myositis (IBM) - a progressive muscle-wasting disease with no approved treatments - alongside pipeline work in T-cell large granular lymphocytic leukemia and T/NK-cell lymphomas.

- **Founded:** 2015
- **Headquarters:** Newton, Massachusetts, United States
- **Founders:** Stefano Gulla (Co-Founder & former CEO), Steven A. Greenberg, M.D. (Scientific Co-Founder & Chief Scientific Advisor)
- **Team size:** ~43 employees
- **Products:** Ulviprubart (ABC008), IBM program, T-LGLL program, T and NK cell lymphoma program
- **Notable:** Raised a $200 million Series C in February 2025, one of the larger rare-disease rounds of the year, Total funding reported at roughly $407M+ across multiple rounds, Advanced ulviprubart into a registrational Phase II/III MUSCLE trial for inclusion body myositis

## Products & services

- **Ulviprubart (ABC008)** — First-in-class investigational humanized monoclonal antibody targeting KLRG1, designed to selectively deplete highly cytotoxic T and NK cells. Lead indication is inclusion body myositis (IBM).
- **IBM program** — Clinical development of ulviprubart for inclusion body myositis, a progressive autoimmune muscle-wasting disease affecting roughly 50,000 people across the U.S. and Europe with no approved therapy.
- **T-LGLL program** — Pipeline development of KLRG1-targeting therapy for T-cell large granular lymphocytic leukemia.
- **T and NK cell lymphoma program** — Earlier-stage oncology development applying the KLRG1 depletion approach to T and NK cell lymphomas.

## Achievements

- Raised a $200 million Series C in February 2025, one of the larger rare-disease rounds of the year
- Total funding reported at roughly $407M+ across multiple rounds
- Advanced ulviprubart into a registrational Phase II/III MUSCLE trial for inclusion body myositis
- Received FDA orphan drug designation for its lead program
- Translated a 2019 academic finding on KLRG1+ T cells into a first-in-class clinical antibody

## Latest updates

- **2026-03** — Abcuro presented Phase II/III MUSCLE study results for ulviprubart in IBM; the trial missed its primary endpoints, though the company highlighted slowing of disease progression in a lower-dose group and pre-specified patient subsets.
- **2025-02** — Closed $200M Series C led by NEA with Foresite Capital, to fund the registrational MUSCLE trial; initial data expected in first half of 2026.

## Links

- Website: https://abcuro.com
- LinkedIn: http://www.linkedin.com/company/abcuro-inc
- Twitter/X: https://twitter.com/abcuro

---

Profile page: https://yespress.io/abcuro-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-16